Cyxone Concludes T20K's Preclinical Program Following Positive Results in Toxicology Studies

STOCKHOLM, Nov. 28, 2018 /PRNewswire/ -- Cyxone (publ) announced today that the preclinical program for drug candidate T20K in multiple sclerosis (MS) has been concluded following positive results in the toxicology studies. The drug candidate T20K has now shown to be safe for people to...

from PR Newswire: https://ift.tt/2PZjJmj